3,4-dihydroxyphenylacetic acid has been researched along with alpha-synuclein in 42 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (35.71) | 29.6817 |
| 2010's | 22 (52.38) | 24.3611 |
| 2020's | 5 (11.90) | 2.80 |
| Authors | Studies |
|---|---|
| Haass, C; Haid, S; Kahle, PJ; Neumann, M; Okochi, M; Ozmen, L; Rathke-Hartlieb, S; Schulz, JB | 1 |
| Björklund, A; Burger, C; Johansen, TE; Kirik, D; Lundberg, C; Mandel, RJ; Muzyczka, N; Rosenblad, C | 1 |
| Alessandrí, MG; Fornai, F; Geppert, M; Jahn, R; Schlüter, OM; Südhof, TC; Takamori, S | 1 |
| Behrouz, B; Drolet, RE; Goudreau, JL; Lookingland, KJ | 2 |
| Ali, SF; Cawthon, D; McCastlain, KA; Slikker, W; Xu, Z | 1 |
| Dawson, TM; Dawson, VL; Mandir, AS; Shimoji, M; Zhang, L | 1 |
| Biagioni, F; Busceti, CL; di Poggio, AB; Ferrucci, M; Fornai, F; Giusiani, M; Lazzeri, G; Lenzi, P; Natale, G; Paparelli, A; Ruggieri, S | 1 |
| Cherng, CG; Hsu, HC; Kuo, YM; Liao, PC; Yu, L | 1 |
| Galvin, JE | 1 |
| Giasson, BI; Ischiropoulos, H; Lynch, DR; Mazzulli, JR; Mishizen, AJ; Nagatsu, T; Nakashima, A; Ota, A; Thomas, SA | 1 |
| Di Monte, DA; Guillot, TS; Hatcher, JM; Jones, DP; McCormack, AL; Miller, GW; Pennell, KD; Richardson, JR | 1 |
| Burke, WJ; Chung, HD; Franko, MW; Galvin, JE; Gan, Q; Kumar, VB; Li, SW; O'Dell, M; Pan, Y; Pandey, N; Panneton, WM | 1 |
| Debetto, P; Giusti, P; Guidolin, D; Negro, A; Peroni, D; Recchia, A; Rota, D; Skaper, SD | 1 |
| Fink, AL; Gallagher, A; Hong, DP; Long, C; Uversky, VN; Zhou, W | 1 |
| Cao, P; Feng, Z; Huang, Y; Moise, AR; Palczewski, K; Pehek, EA; Yuan, Y | 1 |
| Björklund, T; Buck, K; Kirik, D; Ulusoy, A | 1 |
| Inmozhi Sivakamasundari, R; Rekha, KR; Santha, K; Selvakumar, GP | 1 |
| Davydova, TV; Fomina, VG; Gruden, MA; Kudrin, VS; Morozova-Roche, LA; Narkevich, VB; Sewell, RD; Wang, C | 1 |
| Cooney, A; Goldstein, DS; Gross, D; Jinsmaa, Y; Sharabi, Y; Sullivan, P | 1 |
| Goldstein, DS; Kopin, IJ; Sharabi, Y | 1 |
| Cooney, A; Goldstein, DS; Jinsmaa, Y; Sharabi, Y; Sullivan, P | 1 |
| Chan, HM; Shao, Y | 1 |
| Araujo, GD; Coelho-Cerqueira, E; Domont, GB; Eliezer, D; Follmer, C; Pinheiro, AS; Yatabe-Franco, DY | 1 |
| Bubacco, L; Plotegher, N | 1 |
| Goldstein, DS; Jinsmaa, Y; Sharabi, Y; Sullivan, P | 1 |
| Bax, A; DuMond, JF; Levine, RL; Werner-Allen, JW | 1 |
| Berti, G; Bisaglia, M; Bubacco, L; Casella, L; Dalla Serra, M; Ferrari, E; Girotto, S; Greggio, E; Lunelli, L; Perego, C; Plotegher, N; Tessari, I; Veronesi, M; Zanetti, M | 1 |
| Bax, A; Levine, RL; Werner-Allen, JW | 1 |
| Diwakar, S; Melethadathil, N; Nair, B; Sasidharakurup, H | 1 |
| Goldstein, DS; Sharabi, Y | 1 |
| Bellen, HJ; Chen, R; D'Amelio, M; Gibbs, RA; Goldstein, DS; Graham, BH; Landrock, KK; Martini-Stoica, H; Stoica, G; Sullivan, P; Yamamoto, S | 1 |
| Bax, A; DuMond, JF; Levine, RL; Monti, S; Werner-Allen, JW | 1 |
| Carmo-Gonçalves, P; Cortines, JR; do Nascimento, LA; Eliezer, D; Follmer, C; Romão, L | 1 |
| do Nascimento, LA; Eliezer, D; Follmer, C; Lima, VA | 1 |
| Burke, WJ; Gillespie, KN; Hsu, FF; Kumar, VB; Lakshmi, VM | 1 |
| Ahn, J; Arellano, J; Fowler, AJ; Hebron, ML; Howard, HH; Lawler, A; Liu, X; Matar, S; Moussa, C; Mundel, EE; Pagan, FL; Peyton, M; Schwartz, SL; Starr, NJ; Torres-Yaghi, Y; Wilmarth, B; Yusuf, N | 1 |
| Goldstein, DS; Isonaka, R; Jinsmaa, Y; Sharabi, Y | 1 |
| Carmo-Gonçalves, P; Follmer, C; Romão, L | 1 |
| Cui, CP; Feng, Y; Gao, S; He, C; Li, BY; Li, KX; Qiao, GF; Sun, J; Sun, X; Wang, HD; Wang, X; Xiong, X; Yan, QX; Yin, RX; Zha, RR | 1 |
| Acquasaliente, L; Bucciantini, M; Fongaro, B; Leri, M; Palazzi, L; Polverino de Laureto, P; Stefani, M | 1 |
| Cappelletto, E; Fongaro, B; Polverino de Laureto, P; Sosic, A; Spolaore, B | 1 |
4 review(s) available for 3,4-dihydroxyphenylacetic acid and alpha-synuclein
| Article | Year |
|---|---|
Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Dopamine; Humans; Oxidative Stress; Parkinson Disease; Substantia Nigra | 2006 |
Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Apoptosis; Catecholamines; Humans; Lipid Peroxidation; Neurodegenerative Diseases; Neurons; Oxidation-Reduction; Parkinson Disease | 2014 |
Lysines, Achilles' heel in alpha-synuclein conversion to a deadly neuronal endotoxin.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehydes; alpha-Synuclein; Brain; Dopamine; Humans; Lysine; Metabolism; Neurodegenerative Diseases; Neurons | 2016 |
The heart of PD: Lewy body diseases as neurocardiologic disorders.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Catecholamines; Dopamine; Heart; Humans; Lewy Bodies; Lewy Body Disease; Multiple System Atrophy; Myocardium; Neuroimaging; Neurons; Parkinson Disease; Sympathetic Nervous System | 2019 |
1 trial(s) available for 3,4-dihydroxyphenylacetic acid and alpha-synuclein
| Article | Year |
|---|---|
Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Aged, 80 and over; alpha-Synuclein; Biomarkers; Brain; Cohort Studies; Dopamine; Dose-Response Relationship, Drug; Double-Blind Method; Drugs, Investigational; Homovanillic Acid; Humans; Membrane Glycoproteins; Middle Aged; Parkinson Disease; Placebos; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Immunologic | 2019 |
37 other study(ies) available for 3,4-dihydroxyphenylacetic acid and alpha-synuclein
| Article | Year |
|---|---|
Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amino Acid Substitution; Animals; Corpus Striatum; Dopamine; Homovanillic Acid; Humans; Mice; Mice, Transgenic; Nerve Tissue Proteins; Neurites; Neurons; Parkinson Disease; Parkinsonian Disorders; Promoter Regions, Genetic; Substantia Nigra; Synucleins; Thy-1 Antigens; Tyrosine 3-Monooxygenase | 2001 |
Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Behavior, Animal; Cell Count; Cell Death; Corpus Striatum; Dependovirus; Disease Models, Animal; Disease Progression; Dopamine; Gene Targeting; Genetic Vectors; Humans; Motor Activity; Nerve Tissue Proteins; Neurodegenerative Diseases; Neurons; Organ Specificity; Parkinson Disease; Rats; Rats, Sprague-Dawley; Substantia Nigra; Synucleins; Tissue Distribution; Transduction, Genetic; Tyrosine 3-Monooxygenase | 2002 |
Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; alpha-Synuclein; Animals; Antibodies; Blastomeres; Blotting, Southern; Corpus Striatum; Disease Models, Animal; DNA Primers; Dopamine; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Glutamic Acid; Hippocampus; Homovanillic Acid; Humans; Immunoblotting; Immunohistochemistry; Methamphetamine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; MPTP Poisoning; Nerve Tissue Proteins; Neurons; Parkinsonian Disorders; Piperazines; Rats; Reserpine; Serotonin; Stem Cells; Subcellular Fractions; Substantia Nigra; Synucleins; Tyrosine 3-Monooxygenase | 2003 |
Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Blotting, Western; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Lactic Acid; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Neostriatum; Nerve Tissue Proteins; Neuropeptides; Substantia Nigra; Synucleins; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2004 |
Selective alterations of gene expression in mice induced by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; beta-Synuclein; Brain Chemistry; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Gene Expression; Gene Expression Regulation; Homovanillic Acid; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Synucleins; Tyrosine 3-Monooxygenase; Vesicular Biogenic Amine Transport Proteins | 2005 |
Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Homovanillic Acid; Humans; Immunohistochemistry; Inclusion Bodies; Male; Mice; Mice, Inbred C57BL; MPTP Poisoning; Nerve Tissue Proteins; Neurons; Substantia Nigra; Synucleins; Tyrosine 3-Monooxygenase; Ubiquitin | 2005 |
Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; Alkanes; alpha-Synuclein; Amides; Amphetamine; Analysis of Variance; Animals; Blotting, Western; Dopamine; Dopamine Uptake Inhibitors; Gene Expression Regulation; Glutamate Decarboxylase; Homovanillic Acid; Immunohistochemistry; Inclusion Bodies; Isoenzymes; Mice; Mice, Inbred C57BL; Microscopy, Electron, Transmission; N-Methyl-3,4-methylenedioxyamphetamine; Nerve Tissue Proteins; Neurons; Substantia Nigra; Synucleins; Tyrosine 3-Monooxygenase | 2005 |
Local proteins associated with methamphetamine-induced nigrostriatal dopaminergic neurotoxicity.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Anisomycin; Blotting, Western; Corpus Striatum; Dopamine; Electrophoresis, Gel, Two-Dimensional; Fever; Male; Mass Spectrometry; Methamphetamine; Mice; Mice, Inbred Strains; Nerve Tissue Proteins; Neurotoxins; Protein Synthesis Inhibitors; Substantia Nigra; Synucleins; Ubiquitin; Ubiquitin Thiolesterase | 2005 |
Substrate-mediated enhancement of phosphorylated tyrosine hydroxylase in nigrostriatal dopamine neurons: evidence for a role of alpha-synuclein.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Corpus Striatum; Dopamine; Dopamine Antagonists; Homovanillic Acid; Mice; Mice, Inbred C57BL; Mice, Knockout; Neurons; Phosphorylation; Polymerase Chain Reaction; Raclopride; Substantia Nigra; Tyrosine 3-Monooxygenase | 2006 |
Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amino Acid Substitution; Animals; Catechols; Cell Differentiation; Cell Line, Tumor; Cerebral Cortex; Corpus Striatum; Cytosol; Dopamine; Humans; Levodopa; Mice; Mice, Transgenic; Mutation, Missense; Nerve Degeneration; Neuroblastoma; Oxidation-Reduction; Parkinson Disease; Parkinsonian Disorders; Protein Conformation; Recombinant Fusion Proteins; Solubility; Transfection; Tretinoin; Tyrosine 3-Monooxygenase | 2006 |
Dieldrin exposure induces oxidative damage in the mouse nigrostriatal dopamine system.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Analysis of Variance; Animals; Chromatography, High Pressure Liquid; Cocaine; Corpus Striatum; Dieldrin; Dopamine; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Gene Expression Regulation; Glutathione; Homovanillic Acid; Male; Mice; Mice, Inbred C57BL; Organ Culture Techniques; Oxidative Stress; Protein Carbonylation; Substantia Nigra | 2007 |
Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Blotting, Western; Brain; Cells, Cultured; Dopamine; Immunohistochemistry; Lewy Bodies; Microscopy, Confocal; Monoamine Oxidase; Neurons; Rats; Rats, Sprague-Dawley | 2008 |
Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; alpha-Synuclein; Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Dopamine Agonists; Gene Expression Regulation; Gene Products, tat; Genetic Vectors; Green Fluorescent Proteins; Male; Motor Activity; Oxidopamine; Parkinson Disease; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase | 2008 |
At low concentrations, 3,4-dihydroxyphenylacetic acid (DOPAC) binds non-covalently to alpha-synuclein and prevents its fibrillation.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amyloid; Catechols; Homogentisic Acid; Hydroquinones; Microscopy, Electron, Transmission; Oxidation-Reduction; Protein Binding | 2009 |
Alpha-synuclein disrupted dopamine homeostasis leads to dopaminergic neuron degeneration in Caenorhabditis elegans.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Animals, Genetically Modified; Caenorhabditis elegans; Dopamine; Female; Green Fluorescent Proteins; Homeostasis; Humans; Male; Microscopy, Confocal; Motor Activity; Nerve Degeneration; Synaptic Vesicles; Vesicular Monoamine Transport Proteins | 2010 |
Dysregulated dopamine storage increases the vulnerability to α-synuclein in nigral neurons.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Analysis of Variance; Animals; Chromatography, High Pressure Liquid; Dopamine; Dopamine Plasma Membrane Transport Proteins; Electrochemistry; Genetic Vectors; Green Fluorescent Proteins; Humans; Hydroxyindoleacetic Acid; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neurons; RNA, Small Interfering; Serotonin; Substantia Nigra; Tyrosine 3-Monooxygenase; Vesicular Monoamine Transport Proteins | 2012 |
Geraniol attenuates α-synuclein expression and neuromuscular impairment through increase dopamine content in MPTP intoxicated mice by dose dependent manner.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Acyclic Monoterpenes; alpha-Synuclein; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Lewy Bodies; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase; MPTP Poisoning; Neuromuscular Diseases; Parkinson Disease, Secondary; Substantia Nigra; Terpenes | 2013 |
Intranasal administration of alpha-synuclein aggregates: a Parkinson's disease model with behavioral and neurochemical correlates.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Intranasal; alpha-Synuclein; Amyloid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Homovanillic Acid; Hypokinesia; Male; Mice; Mice, Inbred C57BL; Motor Activity; Muscle Rigidity; Parkinsonian Disorders; Protein Aggregates; Substantia Nigra | 2014 |
Divalent metal ions enhance DOPAL-induced oligomerization of alpha-synuclein.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Antioxidants; Ascorbic Acid; Cations, Divalent; Chelating Agents; Copper; Dopamine; Edetic Acid; Humans; Iron; Manganese; PC12 Cells; Phenylethyl Alcohol; Protein Aggregates; Protein Multimerization; Rats | 2014 |
The serotonin aldehyde, 5-HIAL, oligomerizes alpha-synuclein.
Topics: 3,4-Dihydroxyphenylacetic Acid; 5-Hydroxytryptophan; alpha-Synuclein; Animals; Dopamine; Hydroxyindoleacetic Acid; Isoenzymes; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; PC12 Cells; Polymerization; Rats; Serotonin | 2015 |
Effects of methylmercury on dopamine release in MN9D neuronal cells.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Cell Line; Cell Survival; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Dose-Response Relationship, Drug; Environmental Pollutants; Gene Expression Regulation; Homovanillic Acid; Kinetics; Methylmercury Compounds; Mice; Monoamine Oxidase; Nerve Tissue Proteins; RNA, Messenger; Tyrosine 3-Monooxygenase | 2015 |
Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL).
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amyloid; Animals; Cell Membrane; Dopamine; Dopaminergic Neurons; Humans; Lysine; Membrane Lipids; Oxidation-Reduction; Parkinson Disease; Rats; Schiff Bases; Substantia Nigra | 2015 |
DOPAL is transmissible to and oligomerizes alpha-synuclein in human glial cells.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Catecholamines; Cell Line; Dose-Response Relationship, Drug; Glioblastoma; Humans; Mutation; Neuroglia; PC12 Cells; Protein Aggregates; Rats; Subcellular Fractions; Time Factors | 2016 |
Toxic Dopamine Metabolite DOPAL Forms an Unexpected Dicatechol Pyrrole Adduct with Lysines of α-Synuclein.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Cross-Linking Reagents; Humans; Limit of Detection; Pyrroles | 2016 |
DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Biological Transport; Cell Line; Cell Membrane; Humans; Magnetic Resonance Spectroscopy; Mice; Neurons; Permeability; Protein Aggregates; Protein Aggregation, Pathological; Protein Binding; Protein Multimerization; Synaptic Vesicles; Tandem Mass Spectrometry | 2017 |
Superoxide is the critical driver of DOPAL autoxidation, lysyl adduct formation, and crosslinking of α-synuclein.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Binding Sites; Cross-Linking Reagents; Enzyme Activation; Lysine; Oxidation-Reduction; Oxygen; Protein Binding; Pyrroles; Reactive Oxygen Species; Superoxide Dismutase | 2017 |
A Systems Model of Parkinson's Disease Using Biochemical Systems Theory.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Biomarkers; Brain; Cell Death; Computer Simulation; Disease Progression; Dopamine; Dopaminergic Neurons; Gene Expression Regulation; Humans; Models, Statistical; Neurofibrillary Tangles; Parkinson Disease; Reactive Oxygen Species; Signal Transduction; Stochastic Processes; Systems Theory; tau Proteins; Ubiquitin-Protein Ligases | 2017 |
Pleiotropic neuropathological and biochemical alterations associated with Myo5a mutation in a rat Model.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Central Nervous System; Disease Models, Animal; Electron Transport Chain Complex Proteins; Heredodegenerative Disorders, Nervous System; Microscopy, Electron, Transmission; Mutation; Myosin Heavy Chains; Myosin Type V; Phosphorylation; Rats; Rats, Mutant Strains; tau Proteins | 2018 |
Isoindole Linkages Provide a Pathway for DOPAL-Mediated Cross-Linking of α-Synuclein.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Cross-Linking Reagents; Humans; Isoindoles; Models, Molecular; Neurons; Oxidation-Reduction; Parkinson Disease | 2018 |
Exploring the role of methionine residues on the oligomerization and neurotoxic properties of DOPAL-modified α-synuclein.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Cell Survival; Cells, Cultured; Humans; Hydrogen Peroxide; Methionine; Mice; Mutation; Neurons; Oxidants; Oxidation-Reduction; Protein Multimerization; Protein Processing, Post-Translational | 2018 |
Role of Parkinson's Disease-Linked Mutations and N-Terminal Acetylation on the Oligomerization of α-Synuclein Induced by 3,4-Dihydroxyphenylacetaldehyde.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylation; alpha-Synuclein; Dopamine; Dopaminergic Neurons; Humans; Membrane Lipids; Mutation; Oxidation-Reduction; Parkinson Disease; Protein Multimerization; Protein Processing, Post-Translational | 2019 |
Aldehyde adducts inhibit 3,4-dihydroxyphenylacetaldehyde-induced α-synuclein aggregation and toxicity: Implication for Parkinson neuroprotective therapy.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehydes; alpha-Synuclein; Animals; Indans; Neuroprotective Agents; Parkinson Disease; PC12 Cells; Rats | 2019 |
3,4-Dihydroxyphenylacetaldehyde Is More Efficient than Dopamine in Oligomerizing and Quinonizing
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; alpha-Synuclein; Antioxidants; Cell Line; Copper; Dopamine; Humans; Monoamine Oxidase; Monophenol Monooxygenase; Oligodendroglia; Oxidation-Reduction; Parkinson Disease; Protein Binding; Protein Conformation; Tolcapone | 2020 |
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Dopamine; Humans; Isoquinolines; Mice; Neurons; Primary Cell Culture | 2020 |
Parkinson-like early autonomic dysfunction induced by vagal application of DOPAL in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Autonomic Nervous System Diseases; Baroreflex; Blood Pressure; Electrocardiography; Hypotension, Orthostatic; Male; Mitochondria, Heart; Myocardium; Myocytes, Cardiac; Nodose Ganglion; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Vagus Nerve | 2021 |
Structural Features and Toxicity of α-Synuclein Oligomers Grown in the Presence of DOPAC.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amyloid; Cell Proliferation; Dopamine; Dopaminergic Neurons; Humans; Oxidative Stress; Parkinson Disease; Phenylethyl Alcohol; Protein Aggregation, Pathological; Protein Multimerization | 2021 |
3,4-Dihydroxyphenylethanol and 3,4-dihydroxyphenylacetic acid affect the aggregation process of E46K variant of α-synuclein at different extent: Insights into the interplay between protein dynamics and catechol effect.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Catechols; Dopamine; Humans; Parkinson Disease; Phenylethyl Alcohol | 2022 |